Voyager TherapeuticsVYGR
Market Cap: $334M
About: Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.
Employees: 162
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
63% more call options, than puts
Call options by funds: $633K | Put options by funds: $388K
4.03% more ownership
Funds ownership: 64.13% [Q1] → 68.16% (+4.03%) [Q2]
2% less repeat investments, than reductions
Existing positions increased: 41 | Existing positions reduced: 42
4% less funds holding
Funds holding: 131 [Q1] → 126 (-5) [Q2]
10% less capital invested
Capital invested by funds: $324M [Q1] → $293M (-$30.9M) [Q2]
18% less first-time investments, than exits
New positions opened: 23 | Existing positions closed: 28
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
HC Wainwright & Co. Patrick Trucchio 31% 1-year accuracy 41 / 131 met price target | 390%upside $30 | Buy Reiterated | 20 Aug 2024 |
Wedbush Laura Chico 49% 1-year accuracy 36 / 74 met price target | 14%upside $7 | Neutral Maintained | 7 Aug 2024 |
HC Wainwright & Co. Patrick Trucchio 31% 1-year accuracy 41 / 131 met price target | 390%upside $30 | Buy Reiterated | 31 Jul 2024 |
Financial journalist opinion
Based on 3 articles about VYGR published over the past 30 days